Hyderabad News Desk

The Marginal Zone Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Marginal Zone Lymphoma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Marginal Zone Lymphoma Market.

Some of the key takeaways from the Marginal Zone Lymphoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Marginal Zone Lymphoma treatment therapies with a considerable amount of success over the years. 
• Marginal Zone Lymphoma companies working in the treatment market are Carna Biosciences, Hutchmed, Incyte, Innovent, MorphoSys, Beigene, InnoCare Pharma, Beijing Mabworks Biotech Co., MEI Pharma, Inc., Kyowa Kirin, ADC Therapeutics, Loxo Oncology, Adicet Bio, Celldex Therapeutics Inc, and others, are developing therapies for the Marginal Zone Lymphoma treatment 

• Emerging Marginal Zone Lymphoma therapies in the different phases of clinical trials are- AS-1763, Amdizalisib (HMPL689), Parsaclisib (IBI376), Tafasitamab, Zanubrutinib, Orelabrutinib, Tafasitamab, MIL62, Zandelisib, Loncastuximab, LOXO-305, ADI-001, CDX-1140, and others are expected to have a significant impact on the Marginal Zone Lymphoma market in the coming years.  
• In August 2022, The first patient in a company-sponsored Phase I/II research assessing a conveniently available, cryopreserved formulation of GDA-201 for the treatment of follicular, diffuse large B cell lymphomas, as well as marginal zone lymphoma or mantle cell lymphoma, has been dosed, according to Gamida Cell.
• In August 2022, The China National Medical Products Administration (NMPA) approved Orelabrutinib’s supplemental New Drug Application (sNDA) for the treatment of patients with relapsed or refractory Marginal Zone Lymphoma (R/R MZL).
• In June 2022, In LOTIS-7, a Phase 1b clinical trial assessing ZYNLONTA in conjunction with various anti-cancer medications in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, ADC Therapeutics reported that the first patient has received a dosage. ZYNLONTA in combination with polatuzumab vedotin will be tested for safety and efficacy in the first arm of the LOTIS-7 open-label, multi-center, multi-arm Phase Ib trial. The patients in this trial will be those with relapsed or refractory B-cell non-Hodgkin lymphomas, such as diffuse large B-cell lymphoma, high grade B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and Burkitt lymphoma.
• In May 2022, The CIRLL clinical trial (CIRM-0001), a Phase I/II experiment, is being evaluated by Oncternal Therapeutics for zilovertamab in combination with ibrutinib in two different patient groups: one for MCL and the other for CLL. The dose-finding cohorts for MCL and CLL, the dose-expansion cohort for MCL and CLL, and the randomized Phase II cohort for CLL have all reached enrollment completion. Recently, up to ten patients with marginal zone lymphoma (MZL) were included to a dose-expansion group. We anticipate that enrollment will start in Q2 2022. 

Marginal Zone Lymphoma Overview

A subset of indolent (slow-growing) NHL B-cell lymphomas known as marginal zone B-cell lymphoma or marginal zone lymphoma (MZL) make up for 5–17% of all NHL cases.

Get a Free Sample PDF Report to know more about Marginal Zone Lymphoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/marginal-zone-lymphoma-pipeline-insight

Emerging Marginal Zone Lymphoma Drugs Under Different Phases of Clinical Development Include:

• AS-1763: Carna Biosciences
• Amdizalisib (HMPL689): Hutchmed
• Parsaclisib (IBI376): Incyte/Innovent
• Tafasitamab: MorphoSys/Incyte
• Zanubrutinib: Beigene
• Orelabrutinib: InnoCare Pharma
• Tafasitamab: Incyte Corporation
• MIL62: Beijing Mabworks Biotech Co.
• Zandelisib: MEI Pharma, Inc./Kyowa Kirin         
• Loncastuximab: ADC Therapeutics
• LOXO-305: Loxo Oncology
• ADI-001: Adicet Bio
• CDX-1140: Celldex Therapeutics Inc

Marginal Zone Lymphoma Route of Administration

Marginal Zone Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Marginal Zone Lymphoma Molecule Type

Marginal Zone Lymphoma Products have been categorized under various Molecule types, such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Marginal Zone Lymphoma Pipeline Therapeutics Assessment

• Marginal Zone Lymphoma Assessment by Product Type
• Marginal Zone Lymphoma By Stage and Product Type
• Marginal Zone Lymphoma Assessment by Route of Administration
• Marginal Zone Lymphoma By Stage and Route of Administration
• Marginal Zone Lymphoma Assessment by Molecule Type
• Marginal Zone Lymphoma by Stage and Molecule Type

DelveInsight’s Marginal Zone Lymphoma Report covers around 50+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Marginal Zone Lymphoma product details are provided in the report. Download the Marginal Zone Lymphoma pipeline report to learn more about the emerging Marginal Zone Lymphoma therapies

Some of the key companies in the Marginal Zone Lymphoma Therapeutics Market include:

Key companies developing therapies for Marginal Zone Lymphoma are – Incyte Corporation, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Incyte Corporation, Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc, Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, and others.

Marginal Zone Lymphoma Pipeline Analysis:

The Marginal Zone Lymphoma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Marginal Zone Lymphoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Marginal Zone Lymphoma Treatment.
• Marginal Zone Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Marginal Zone Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Marginal Zone Lymphoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Marginal Zone Lymphoma drugs and therapies

Marginal Zone Lymphoma Pipeline Market Drivers

• Increasing Prevalence, increased research and development are some of the important factors that are fueling the Marginal Zone Lymphoma Market.

Marginal Zone Lymphoma Pipeline Market Barriers

• However, therapies with moderately good patient outcomes, long treatment course and other factors are creating obstacles in the Marginal Zone Lymphoma Market growth.

Scope of Marginal Zone Lymphoma Pipeline Drug Insight    

• Coverage: Global
• Key Marginal Zone Lymphoma Companies: Carna Biosciences, Hutchmed, Incyte, Innovent, MorphoSys, Beigene, InnoCare Pharma, Beijing Mabworks Biotech Co., MEI Pharma, Inc., Kyowa Kirin, ADC Therapeutics, Loxo Oncology, Adicet Bio, Celldex Therapeutics Inc, and others
• Key Marginal Zone Lymphoma Therapies: AS-1763, Amdizalisib (HMPL689), Parsaclisib (IBI376), Tafasitamab, Zanubrutinib, Orelabrutinib, Tafasitamab, MIL62, Zandelisib, Loncastuximab, LOXO-305, ADI-001, CDX-1140, and others
• Marginal Zone Lymphoma Therapeutic Assessment: Marginal Zone Lymphoma current marketed and Marginal Zone Lymphoma emerging therapies
• Marginal Zone Lymphoma Market Dynamics: Marginal Zone Lymphoma market drivers and Marginal Zone Lymphoma market barriers 

Request for Sample PDF Report for Marginal Zone Lymphoma Pipeline Assessment and clinical trials

Table of Contents

1. Marginal Zone Lymphoma Report Introduction

2. Marginal Zone Lymphoma Executive Summary

3. Marginal Zone Lymphoma Overview

4. Marginal Zone Lymphoma- Analytical Perspective In-depth Commercial Assessment

5. Marginal Zone Lymphoma Pipeline Therapeutics

6. Marginal Zone Lymphoma Late Stage Products (Phase II/III)

7. Marginal Zone Lymphoma Mid Stage Products (Phase II)

8. Marginal Zone Lymphoma Early Stage Products (Phase I)

9. Marginal Zone Lymphoma Preclinical Stage Products

10. Marginal Zone Lymphoma Therapeutics Assessment

11. Marginal Zone Lymphoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Marginal Zone Lymphoma Key Companies

14. Marginal Zone Lymphoma Key Products

15. Marginal Zone Lymphoma Unmet Needs

16 . Marginal Zone Lymphoma Market Drivers and Barriers

17. Marginal Zone Lymphoma Future Perspectives and Conclusion

18. Marginal Zone Lymphoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services